Patents Examined by Amy Lewis
-
Patent number: 7863272Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.Type: GrantFiled: June 14, 2004Date of Patent: January 4, 2011Assignee: M's Science CorporationInventors: Donna Oksenberg, Roman Urfer
-
Patent number: 7829562Abstract: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes faster functional recovery.Type: GrantFiled: September 16, 2005Date of Patent: November 9, 2010Assignee: M's Science CorporationInventors: Mehrdad Shamloo, Donna Oksenberg, Roman Urfer
-
Patent number: 7750045Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: GrantFiled: August 17, 2005Date of Patent: July 6, 2010Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Patent number: 7741374Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: September 10, 2009Date of Patent: June 22, 2010Assignee: Mutual Pharmaceutical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Patent number: 7741373Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.Type: GrantFiled: July 13, 2009Date of Patent: June 22, 2010Assignee: Mutual Pharmacuetical Company, Inc.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Patent number: 7728042Abstract: The invention relates to a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics. The invention also relates to transdermal pharmaceutical composition consists of an estrogen and a progestin component as well as a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl myristate and a hyaluronic acid salt or complex. The invention can be applied for transdermal hormone replacement therapy and for other transdermal depending on the active principles included.Type: GrantFiled: October 6, 2004Date of Patent: June 1, 2010Assignee: Richter Gedeon Vegyeszeti Gyar RTInventors: Istvan Eros, Ildiko Pannonhalmine Csoka, Erzsebet Soosne Csanyi, Attila Bodis, Erzsebet Lapis, Erzsebet Francsicsne Czinege, Emoke Kissne Csikos, Janos Illes
-
Patent number: 7662802Abstract: A complex of glucosamine having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having a pKa of less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers, povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated complex will be stable upon exposure to ambient temperature and/or the atmosphere.Type: GrantFiled: March 31, 2007Date of Patent: February 16, 2010Assignee: Gluconova, LLCInventors: Vilas M. Chopdekar, Michael J. Torntore
-
Patent number: 7662803Abstract: A method of treating a warm-blood vertebrate. The vertebrate may be a human being or a lower animal. The treatment method involves administering to the vertebrate in need of such treatment a pharmaceutically effective amount of a complex of halide-free glucosamine and a therapeutic drug having a pKa of less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers, povidone homopolymers and copolymers, polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant polymer-coated complex will be stable upon exposure to ambient temperature and/or the atmosphere.Type: GrantFiled: March 31, 2007Date of Patent: February 16, 2010Assignee: Gluconova, LLCInventors: Alan Cowan, Robert B. Raffa, Ronald J. Tallarida
-
Patent number: 7648993Abstract: mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.Type: GrantFiled: December 17, 2004Date of Patent: January 19, 2010Assignees: Brown University, Emory UniversityInventors: Mark F. Bear, Kimberly M. Huber, Stephen T. Warren
-
Patent number: 7638510Abstract: The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.Type: GrantFiled: February 16, 2004Date of Patent: December 29, 2009Assignee: Novartis AGInventors: Graeme Bilbe, John F. Cryan, Conrad Gentsch, Kevin Hall McAllister, Markus Schmutz, Annick Vassout
-
Patent number: 7612071Abstract: The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.Type: GrantFiled: March 9, 2005Date of Patent: November 3, 2009Assignee: Syntrix Biosystems, Inc.Inventors: Barton Aron Kamen, Peter David Cole, Angela King Smith, John Anthony Zebala
-
Patent number: 7485665Abstract: The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT4) and causing no arteritis and thrombus formation; a medicinal composition for improving the movement of the digestive tract comprising the said ameliorant and a pharmaceutically acceptable carrier; and a treating method for promoting the movement of the digestive tract, which comprises using the said medicinal composition for improving the movement of the digestive tract.Type: GrantFiled: September 12, 2002Date of Patent: February 3, 2009Assignee: Nagase Chemtex CorporationInventors: Akihiko Kitajima, Osamu Kamoda, Akihiro Ohsako, Toshiharu Yanagi
-
Patent number: 7459474Abstract: Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structure where A, B, and R1-R6 are defined herein.Type: GrantFiled: June 10, 2004Date of Patent: December 2, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Leslie A. Robinson, Jaimie K. Rueter, Wilna J. Moree
-
Patent number: 7425559Abstract: A medicine for central diseases which contains as the active ingredient either a compound represented by the general formula (I): (I) (wherein R1 represents hydrogen or C1-6 alkyl; R2 represents C1-6 alkyl, etc.; A represents carbon, etc.; D represents C1-6 alkylene, etc.; E represents carbon, etc.; and Arom represents aryl, etc.) or a pharmacologically acceptable salt of the compound.Type: GrantFiled: July 11, 2002Date of Patent: September 16, 2008Assignee: BTG International LimitedInventors: Tomiichiro Oda, Shigeko Uryu, Shinya Tokuhiro
-
Patent number: 7411005Abstract: The invention provides A composition for increasing milk production in an animal that includes an active compound chosen from calcium isopropyl cresol, calcium isopropyl-o-cresol, lactic acid, or combinations thereof, and calcium carbonate as a buffering agent. The invention also provides a composition for increasing milk production in an animal that includes about 0.1 wt % to about 15 wt % of the total weight of the composition of active compound, wherein the active compound is chosen from calcium isopropyl cresol, calcium isopropyl-o-cresol, and lactic acid, about 40 wt % to about 75 wt % of the total weight of the composition of calcium carbonate, and about 10 wt % to about 60 wt % of the total weight of the composition of at least one carrier.Type: GrantFiled: February 12, 2003Date of Patent: August 12, 2008Assignee: Van Beek Natural Science, LLCInventor: Dusan Ninkov
-
Patent number: 7393862Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.Type: GrantFiled: October 4, 2005Date of Patent: July 1, 2008Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 7390833Abstract: The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis.Type: GrantFiled: November 8, 2004Date of Patent: June 24, 2008Assignee: WyethInventors: Elisabeth A. Morris, Sonya Glasson, Jason Shaoyun Xiang
-
Patent number: 7211599Abstract: The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g.Type: GrantFiled: September 19, 2003Date of Patent: May 1, 2007Assignees: The Regents of the University of California, Cephalon, Inc.Inventors: Dennis A. Carson, Lorenzo M. Leoni, Mary Patricia Corr
-
Patent number: 7196105Abstract: All multiple myeloma cell lines examined showed constitutively active I?B kinase (IKK), I?B? phosphorylation and constitutively active NF-?B. Curcumin, a chemopreventive agent, suppressed constitutive I?B? phosphorylation through inhibition of IKK activity and downregulated NF-?B. Curcumin also downregulated expression of NF-?B-regulated gene products such as I?B?, Bcl-2, Bcl-xL, cyclin D1 and interleukin-6. Consequently, curcumin suppressed multiple myeloma cell proliferation and arrested cells at the G1/S phase of the cell cycle. Curcumin also induced apoptosis and chemosensitivity to vincristine. Overall, results presented herein provide a molecular basis for the treatment of multiple myeloma patients with this pharmacologically safe agent.Type: GrantFiled: June 24, 2003Date of Patent: March 27, 2007Assignee: Research Development FoundationInventor: Bharat Aggarwal
-
Patent number: RE39574Abstract: The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: December 20, 2000Date of Patent: April 17, 2007Assignees: Hadasit Medical Research Services and Development Company Ltd., Agricultural Research Organization Ministry of AgricultureInventors: Mark Pines, Israel Vlodavsky, Arnon Nagler, Hua-Quan Mian